Drug Dependence Due to the Use of Barbiturates: The State of the Art
https://doi.org/10.30629/2618-6667-2023-21-4-86-93
Abstract
Background: currently, the relevance of the formation of drug dependence on barbiturates, despite a significant decrease in the cases of their prescription, remains prevalent. The breadth of the therapeutic effects of barbiturates determines their use in various branches of medicine, despite the risk of developing dependence and withdrawal syndrome, even in the case of taking therapeutic doses. In addition, the non-drug use of barbiturates in order to achieve a narcotic effect remains relevant.
The aim of review: to analyze the data of scientific publications on specific features of the formation of barbituric dependence in various categories of patients, to determine the groups at greatest risk and the possibilities of minimizing the consequences of barbiturate use.
Materials and methods: based on the analysis of databases (PubMed/MEDLINE, RSCI, etc.), the current concepts of mechanism of action of barbiturates and the ways of development of mental and physical dependence were analyzed. The factors provoking the emergence of drug dependence are determined.
Results: the development of drug dependence when taking barbiturates develops rapidly and is dose-dependent. The features of the formation of barbituric dependence and the development of tolerance are characterized. The risk of developing dependence in the therapeutic use of barbiturates is especially high in the elderly.
Conclusions: to prevent and possibly reduce the risk of drug dependence, the main areas of research are proposed, namely, the development of more effective and safe drugs analogs of barbituric acid, as well as the correction of the features of the use of barbituric acid drugs (frequency, dosage, dosage form, etc.).
About the Author
E. V. Titarenko
FSBHI “Medical and Sanitary Department № 174 of the Federal Medical and Biological Agency of Russia”
Russian Federation
Russian Federation
Elena Vadimovna Titarenko, Psychiatrist, Narcologist
Protvino
References
1. Breus EV. Sravnitel’nye osobennosti barbiturovoj i alkogol’noj jencefalopatii. V sb.: Molodezh’ v nauke: Novye argumenty: Mezhdunarodnyj molodezhnyj sbornik nauchnyh statej. Lipeck: Nauchnoe partnerstvo “Argument”, 2018;61–63. (In Russ.).
2. Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH, Young WL. Miller’s Anesthesia. Elsevier Health Sciences, 2009:3084.
3. Racional’naja farmako-anesteziologija: rukovodstvo dlja praktikujushhih vrachej. Pod red. AA Bunjatjana, VM Mizikova. M.: Litterra, 2006;800 s. (In Russ.).
4. Oros GJu, Selemenev VF, Eliseeva TV, Krisilova EV, Mokshina NJa. Primenenie proizvodnyh barbiturovoj kisloty v kachestve lekarstvennyh sredstv (obzor). Sorbcionnye i hromatograficheskie processy. 2007;7(2):315–323. (In Russ.).
5. Skibiski J, Abdijadid S. Barbiturates. StatPearls Publishing; 2022. Bookshelf ID: NBK539731 https://www.ncbi.nlm.nih.gov/books/NBK539731.
6. Majdan M, Mauritz W, Wilbacher I, Brazinova A, Rusnak M, Leitgeb J. Barbiturates use and its effects in patients with severe traumatic brain injury in ve European countries. J Neurotrauma. 2013;30(1):23–29. doi: 10.1089/neu.2012.2554
7. Suddock JT, Cain MD. Barbiturate toxicity. Treasure Island (FL): StatPearls Publishing; 2022. Bookshelf ID: NBK499875.
8. Churjukanov VV, Lemina EJu. Snotvornye sredstva: proshloe, nastojashhee, budushhee. Jeksperimental’naja i klinicheskaja farmakologija. 2018;81(6):41–44. (In Russ.). doi: 10.30906/0869-2092-2018-81-6-40-44
9. Bakumov PA. Famakojepidemiologija snotvornyh sredstv. Novye lekarstva i novosti farmakoterapii. 2001;(12):11–15. (In Russ.).
10. Rabin AG, Glanc VL, Reshetnjak VK. K analizu dejstvija barbituratov na koru bol’shih polusharij. Bjulleten’ jeksperimental’noj biologii i mediciny. 1969;68(11):91–94. (In Russ.).
11. Zalmunin KYu, Mendelevich VD. Chemical and nonchemical addictions in the aspect of comparative addictology. Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova. 2014;114(5–2):3–8. (In Russ.). doi: 10.17116/jnevro2018118123-9
12. Mendelevich VD. Addictophobia in modern psychiatry (benzodiazepines and other psychopharmacological drugs). S.S. Korsakov Journal of Neurology and Psychiatry/Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(1–2):75–81. (In Russ.). doi: 10.17116/jnevro20191191275
13. Roberts DM, Buckley NA. Enhanced elimination in acute barbiturate poisoning — a systematic review. Clin Toxicol (Phila). 2011;49(1):2–12. doi: 10.3109/15563650.2010.550582
14. López-Muñoz F, Ucha-Udabe R, Alamo-González C. Un siglo de barbitúricos en neurologia [A century of barbiturates in neurology]. Rev Neurol. 2004;39(8):767– 775. (In Spanish). PMID: 15514906.
15. Barbiturate intoxication and overdose. MedlinePlus. National Library of Medicine. https://medlineplus.gov/ency/article/000951.htm.
16. Barbiturates drug profile. European monitoring center for drugs and drug addiction (EMCDDA). https://www.emcdda.europa.eu/publications/drug-profiles/barbiturates_en#.
17. Sarrecchia C, Sordillo P, Rocchi G. Barbiturate withdrawal syndrome: a case associated with the abuse of a headache medication. Ann Ital Med Int. 1998;13(4):237–239. PMID: 10349206.
18. King LA, McDermott S. Drugs of Abuse. In: Moffat AC, Osselton MD, Widdop B (eds). Clarke's Analysis of Drugs and Poisons. 3rd ed. London, 2004;1:37–52.
19. Borisevich SN, Vergun OM, Shmigel’skij AA. Laboratornaja diagnostika ostryh otravlenij barbituratami. Zdravoohranenie (Minsk). 2011;(4):52–55. (In Russ.).
20. Ito T, Suzuki T, Wellman SE, Ho IK. Pharmacology of barbiturate tolerance/dependence: GABAA receptors and molecular aspects. Life Sci. 1996;59(3):169–195. doi: 10.1016/0024-3205(96)00199-3
21. Alkattan A, Alsalameen E, Ahmed A. Central nervous system depressant drugs: updated review. Semantic-scholar. 2021. doi: 10.20944/preprints202101.0503.v1
22. Brjun EA, Agibalova TV, Bedina IA, Buzik OZh, Vinnikova MA, Koshkina EA, Mihajlov MA, Nadezhdin AV, Poplevchenkov KN, Tetenova EJu. Psihicheskie i povedencheskie rasstrojstva, vyzvannye upotrebleniem psihoaktivnyh veshhestv. Sindrom zavisimosti ot psihoaktivnyh veshhestv. Klinicheskie rekomendacii. Narkologija. 2019;18(2):3–59. (In Russ.). doi: 10.25557/1682-8313.2019.01.03.3-59
23. Löscher W, Rogawski M. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia. 2012;53(8):12–25. doi: 10.1111/epi.12025
24. Mathers DA, WAN X, Puil E. Barbiturate activation and modulation of GABA(A) receptors in neocortex. Neuropharmacology. 2007;52(4):1160–1168. doi: 10.1016/j.neuropharm.2006.12.004
25. Smith MC, Riskin BJ. The clinical use of barbiturates in neurological disorders. Drugs. 1991;42(3):365– 378. doi: 10.2165/00003495-199142030-00003
26. Lewis C, Adams N. Phenobarbital. Treasure Island (FL): StatPearls Publishing; 2022. Bookshelf ID: NBK532277.
27. Wong EHF, Leeb-Lundberg LMF, Teichberg VI, Olsen RW. γ-Aminobutyric acid activation of36Cl-fiux in rat hippocampal slices and its potentiation by barbiturates. Brain Research. 1984;303(2):267–275. doi: 10.1016/0006-8993(84)91213-7
28. Liu H, Yao S. Thiopental sodium reduces glutamate extracellular levels in rat intact prefrontal cortex. Exp Brain Res. 2005;167:666–669.
29. Ge ZJ, Zhang LC, Zeng YM, Da TJ, Wang JK, Cui GX, Tan YF, Zhao YP, Liu GJ. Involvement of NMDA receptors in thiopental-induced loss of righting reflex, antinociception and anticonvulsion effects in mice Pharmacology. 2007;80(2–3):127–133. doi: 10.1159/000103252 Epub 2007 May 29. PMID: 17534122.
30. Tomlin SL, Jenkins A, Lieb WR, Franks NP. Preparation of barbiturate optical isomers and their effects on GABA(A) receptors. Anesthesiology. 1999;90(6):1714– 1722. doi: 10.1097/00000542-199906000-00029 PMID: 10360871.
31. Esin GV, Livanov PA, Soldatova VJu, Livanov AS, Pikovskij VJu. Toksicheskie jeffekty barbituratov. Medicinskij alfavit. 2015;1(3):25–30. (In Russ.).
32. Mirhoshimov MBU, Zakirhodzhaev AM, Holova NR, Musamuhamedov SSU, Melibaeva MM. Sovremennye aspekty lechenija jepilepsii. Nauka, tehnika i obrazovanie. 2020;4(68):98–100. (In Russ.).
33. Al’tshuler GN, Afanas’eva GI. Izbiratel’nost’ obmena anionov barbituratov na hlorid na vysokoosnovnom anionite. Himiko-farmacevticheskij zhurnal. 1975;9(2):45–47. (In Russ.).
34. Barbiturates. Drug Enforcement Administration. 2020. https://www.dea.gov/sites/default/files/2020-06/Barbiturates-2020_0.pdf.
35. Lane SJ, Morgan WW. Development of tolerance to chronic barbital treatment in the cerebellar cyclic guanosine monophosphate system and its response to subsequent barbital abstinence. J Pharmacol Exp Ther. 1985;234(3):569–574. PMID: 2993585.
36. Tseng YT, Miyaoka T, Ho IK. Region-specic changes of GABAA receptors by tolerance to and dependence upon pentobarbital. Eur J Pharmacol. 1993;236(1):23–30. doi: 10.1016/0014-2999(93)90222-4
37. Vorob’ev II, Lavrent’ev AA, Suhodolova GN. Ocenka stepeni tjazhesti i prognoz ostryh otravlenij barbituratami. Obshhaja reanimatologija. 2005;1(2):37–39. (In Russ.).
38. Rohlina ML. Sochetannoe upotreblenie narkotikov i drugih psihoaktivnyh veshhestv. Polizavisimost’. Voprosy narkologii. 2014;(2):127–140. (In Russ.).
39. Weaver MF. Prescription sedative misuse and abuse. Yale J Biol Med. 2015;88(3):247–256. PMCID: PMC4553644.
40. Grebenjuk OV, Kazennyh TV, Alifirova VM, Semke VJa, Pajmurzina NJu, Lapina EJu. Klinicheskie prediktory formirovanija lekarstvennoj zavisimosti ot barbituratov u vzroslyh pacientov s parcial’noj jepilepsiej. Sibirskij vestnik psihiatrii i narkologii. 2005;3(37):46–50. (In Russ.).
41. Dutov AA, Gol’tvanica GA, Biktimerov RR, Fedotova AA, Temnikova IV, Levashina EJu. Monoterapija jepilepsii fenobarbitalom i difeninom: sravnitel’nyj analiz. Nevrologicheskij vestnik. 2004;36(1–2):40–42. (In Russ.).
42. Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11– 27. doi: 10.1111/j.1528-1167.2012.03671.x
43. Gusev EI, Burd GS. Lechenie jepilepsii: Racional’noe dozirovanie antikonvul’santov. M.: Izd-vo “Rech’”, 2000:200 р. (In Russ.).
44. Brodie MJ. Management strategies for refractory localization related seizures. Epilepsia. 2001;42(3):27–30.
45. Brodie MJ, Dichter MA. Antiepileptic drugs. New England J Medicine. 1995;334(3):168–175.
46. Eadie MJ. Therapeutic drug monitoring antiepileptic drugs. Brit J Clin. Pharmac. 1998;6(3):185–193.
47. Pyatnitskaya IN. General and particular narcology: A manual for physicians. Moscow: Meditsina Publishers, 2008:640 p. (In Russ.).
48. Oude Voshaar RC. Benzodiazepineverslaving; een stille verslaving onder ouderen [Benzodiazepin addiction: a silent addiction among older people]. Tijdschr Gerontol Geriatr. 2012;43(3):137–147. (In Dutch). PMID: 22826915.
49. Gould RL, Coulson MC, Howard RJ. Efcacy of cognitive behavioral therapy for anxiety disorders in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc. 2012;60(2):218–229.
50. Poluektov MG, Pchelina PV. Insomnia due to hypnotic abuse. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2017;(1):75–80. (In Russ.). doi: 10.17116/jnevro201611611224-29
51. Tropskaja NS, Kisljakova EA, Vilkova IG, Gurman JuV, Kislicyna OS, Zherebcov AV, Borodina EN, Chernen’-kaja TV, Popova TS. Narushenija funkcional’nogo sostojanija CNS, peristal’tiki kishechnika i mikrobiocenoza pri otravlenii barbituratami v jeksperimente. Biomedicina. 2022;18(3):45–49. (In Russ.). doi: 10.33647/2074-5982-18-3-45-49
52. Da Silva AN, Lake AE. Clinical aspects of medication overuse headaches. Headache. 2014;54(1):211–217. doi: 10.1111/head.12223
53. Rae ID. Responses by Australian pharmacologists to respiratory depression caused by opiates and barbiturates. Historical Records of Australian Science. 2022;33(1):1–11. doi: 10.1071/HR21005
54. Sivolap YuP. ‘Silent’ addiction: hypnotic drug abuse. Jeffektivnaja farmakoterapija. 2014;(22):30–35. (In Russ.).
55. Illarionova EA, Syrovatskij IP. Toksikanty iz gruppy barbituratov: ucheb. posobie. Irkutsk: IGMU, 2013:8–9. (In Russ.).
56. Bochanova EN. Pharmacogenetics of antiepileptic drugs (literature review). Kachestvennaya Klinicheskaya Praktika. 2017;(1):51–55. (In Russ.).
Review
For citations:
Titarenko E.V. Drug Dependence Due to the Use of Barbiturates: The State of the Art. Psychiatry (Moscow) (Psikhiatriya). 2023;21(4):86-93. (In Russ.) https://doi.org/10.30629/2618-6667-2023-21-4-86-93
Views:
373
Email this article 
